An update from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:RMD) ) is now available. Resmed Inc has filed a Form ...

ResMed’s market performance aligns with the S&P 500 index Expanding global reach through advanced healthcare solutions ...

The Sleep Apnea Devices industry is set to grow from US$ 6.47 Billion in 2024 to an impressive US$ 12.23 Billion by 2033, at ...

Air Voel, one of Canada’s leading providers of CPAP machines, masks, and sleep-health solutions, today announced the launch of its Sleep Better 2026 Initiative, a nationwide program designed to raise ...

Let's see why these shares could be great long term picks for Aussie investors. The post 2 screaming buy ASX shares I'd hold ...

Discover why ResMed is a top buy with strong fundamentals, robust cash flow, and dividend potential—ideal for recession-proof ...

GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds. ResMed (NYSE: RMD) finds itself in an investment limbo ...

GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds. ResMed faces an uncertain future as GLP-1 weight loss ...

ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker. The ...